Conditions: Difficult Asthma; Severe Persistent Asthma; Hyperventilation SyndromeIntervention: Other: Diagnostic of chronic hyperventilation syndromeSponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de ParisActive, not recruiting – verified May 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)Intervention: Drug: Albuterol Spiromax®Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical IndustriesNot yet recruiting – verified May 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus
Condition: AsthmaInterventions: Drug: Seretide Diskus and charcoal; Drug: Seretide Diskus; Drug: SF Easyhaler and charcoal; Drug: SF EasyhalerSponsors: Orion Corporation, Orion Pharma; Orion Corporation, Orion PharmaRecruiting – verified May 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Condition: AsthmaInterventions: Drug: dupilumab SAR231893 (REGN668); Drug: placeboSponsors: Sanofi; Sanofi; Regeneron PharmaceuticalsNot yet recruiting – verified March 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old
Condition: AsthmaInterventions: Drug: CHF1535 pMDI + AC Plus; Drug: BDP + AC Plus; Drug: Formoterol + AC PlusSponsors: Chiesi Farmaceutici S.p.A.; Chiesi Farmaceutici S.p.A.Completed – verified May 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
CLINICAL PHARMACOLOGY STUDY OF A FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 50µg PLUS FORMOTEROL FUMARATE 6 µg VERSUS THE FREE COMBINATION OF BECLOMETHASONE HFA pMDI AND FORMOTEROL HFA pMDI AVAILABLE ON THE MARKET USING THE AEROCHAMBER PLUS™ SPACER DEVICE IN ASTHMATIC CHILDREN
Condition: AsthmaInterventions: Drug: CHF1535 pMDI + AC Plus; Drug: BDP and Formoterol + AC PlusSponsors: Chiesi Farmaceutici S.p.A.; Chiesi Farmaceutici S.p.A.Completed – verified April 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days